Literature DB >> 8739845

Age-related decrease in responsiveness to L-DOPA is not due to changes in dopamine receptor mRNAs or G protein mRNAs.

M Murata1, Y Aihara, H Yamanouchi, S Yamada, I Kanazawa.   

Abstract

To clarify the cause of the age-related decrease in the responsiveness to L-DOPA seen in parkinsonian patients, we studied age-related changes in the mRNA levels of dopamine receptors (D1, D2) and of G proteins (Gs, Gi, Go) in 22 control human brains aged 50-105 years. Neither the mRNA levels of dopamine receptors or of the G proteins changed with age. Another factor in the receptor-G protein cascade, such as guanine nucleotide binding, may cause the age-related decrease in responsiveness.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8739845     DOI： 10.1007/BF01271245

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  26 in total

1.  Loss of D2 receptors during aging is partially due to decreased levels of mRNA.

Authors:  E R Mesco; J A Joseph; M J Blake; G S Roth
Journal:  Brain Res       Date:  1991-04-05       Impact factor: 3.252

2.  Response fluctuations in Parkinson's disease.

Authors:  R A Roos; C B Vredevoogd; E A van der Velde
Journal:  Neurology       Date:  1990-09       Impact factor: 9.910

3.  Alterations in leukocyte beta-receptor affinity with aging. A potential explanation for altered beta-adrenergic sensitivity in the elderly.

Authors:  R D Feldman; L E Limbird; J Nadeau; D Robertson; A J Wood
Journal:  N Engl J Med       Date:  1984-03-29       Impact factor: 91.245

4.  Repeated reserpine increases striatal dopamine receptor and guanine nucleotide binding protein RNA.

Authors:  P Butkerait; E Friedman
Journal:  J Neurochem       Date:  1993-02       Impact factor: 5.372

5.  Aging and the regulation of striatal dopaminergic mechanisms in mice.

Authors:  P K Randall; J A Severson; C E Finch
Journal:  J Pharmacol Exp Ther       Date:  1981-12       Impact factor: 4.030

6.  Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain.

Authors:  D F Wong; H N Wagner; R F Dannals; J M Links; J J Frost; H T Ravert; A A Wilson; A E Rosenbaum; A Gjedde; K H Douglass
Journal:  Science       Date:  1984-12-21       Impact factor: 47.728

7.  The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression.

Authors:  T Caraceni; G Scigliano; M Musicco
Journal:  Neurology       Date:  1991-03       Impact factor: 9.910

8.  Age-correlated loss of dopaminergic binding sites in human basal ganglia.

Authors:  J A Severson; J Marcusson; B Winblad; C E Finch
Journal:  J Neurochem       Date:  1982-12       Impact factor: 5.372

9.  Dopamine D2 receptor density remains constant in treated Parkinson's disease.

Authors:  M Guttman; P Seeman; G P Reynolds; P Riederer; K Jellinger; W W Tourtellotte
Journal:  Ann Neurol       Date:  1986-05       Impact factor: 10.422

10.  Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease.

Authors:  V Kostic; S Przedborski; E Flaster; N Sternic
Journal:  Neurology       Date:  1991-02       Impact factor: 9.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.